Patents by Inventor Jae Ha Ryu

Jae Ha Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250032629
    Abstract: The present invention relates to a novel peptide that specifically binds to nucleolin and, more specifically, to a peptide represented by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition for diagnosing cancer comprising the peptide, and a composition for preventing or treating cancer comprising the peptide or the conjugate. In the present invention, it has been confirmed that a peptide ligand AGM peptide and mutants thereof, as screened using an MAP synthesis method and an OBOC combination method, specifically bind to cancer cells, and a conjugate thereof with an anticancer drug inhibits cancer growth (in vitro and in vivo). Thus, the NCL-targeting AGM peptide can be effectively used for diagnosis and targeted drug delivery in cancer therapy.
    Type: Application
    Filed: May 18, 2021
    Publication date: January 30, 2025
    Inventors: Jaeil KIM, Jeong-Seok NAM, Jae-Hyun KIM, Jae-Ha RYU
  • Publication number: 20240299487
    Abstract: The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 12, 2024
    Inventors: Jaeil KIM, Jae-Ha RYU, Kyoung-Oh CHO
  • Publication number: 20230287044
    Abstract: The present invention relates to a novel antibacterial peptide and a composition comprising the same as an active ingredient. The novel antibacterial peptide of the present invention exhibits excellent antibacterial activity against antibiotic-resistant bacteria as well as Gram-positive bacteria and Gram-negative bacteria and is low in cytotoxicity and, as such, can be advantageously utilized as an active ingredient in an antibiotic, a cosmetic composition, a food additive, a feed additive, a biotic pesticide, a quasi-drug product, and the like.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 14, 2023
    Inventors: Jae Il KIM, Jae Ha RYU, Shang Hyeon KIM, Sol LEE
  • Publication number: 20230270805
    Abstract: The present invention related to a composition comprising an extract of alder tree or the isolated compounds therefrom for treating and preventing skeleton muscle disease and the use thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 31, 2023
    Inventors: Jae-Ha RYU, Hye Jin LEE, Sunghee CHOI
  • Publication number: 20230212222
    Abstract: The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.
    Type: Application
    Filed: March 11, 2021
    Publication date: July 6, 2023
    Inventors: Jae Il KIM, Jae Ha RYU, Bong Gyu PARK
  • Publication number: 20220323548
    Abstract: The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 13, 2022
    Inventors: Jae Ha RYU, Sang Hyun JOO, Ye Ga PARK
  • Patent number: 11230525
    Abstract: A novel organic sulfur compound, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, containing the same as an active ingredient are provided. The novel organic sulfur compound is capable of excellently inhibiting histone deacetylated (HDAC) enzymes in a concentration of nanomolar or micromolar units and has been found to have an excellent effect against inflammatory diseases, and has been found to be capable of inhibiting the proliferation of cancer.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 25, 2022
    Assignee: Sookmyung Womens University Industry-Academic Cooperation Foundation
    Inventors: Raok Jeon, Jae-Ha Ryu, Hyewon Cho, Yoon-Jung Kim, Sang-Hyun Min, Ji-Hoon Yu
  • Publication number: 20210300865
    Abstract: A novel organic sulfur compound, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, containing the same as an active ingredient are provided. The novel organic sulfur compound is capable of excellently inhibiting histone deacetylated (HDAC) enzymes in a concentration of nanomolar or micromolar units and has been found to have an excellent effect against inflammatory diseases, and has been found to be capable of inhibiting the proliferation of cancer.
    Type: Application
    Filed: July 17, 2017
    Publication date: September 30, 2021
    Applicant: Sookmyung Womens University Industry-Academic Cooperation Foundation
    Inventors: Raok JEON, Jae-Ha RYU, Hyewon CHO, Yoon-Jung KIM, Sang-Hyun MIN, Ji-Hoon YU
  • Patent number: 7884129
    Abstract: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR ? and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: February 8, 2011
    Assignee: Helixir Co., Ltd.
    Inventors: Mi Rim Jin, Jae Ha Ryu, Hyoun Jeong Choi, Hyun Jin Jung, Kyoung Chul Park, Sun Young Kim
  • Publication number: 20080280976
    Abstract: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR ? and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.
    Type: Application
    Filed: May 20, 2008
    Publication date: November 13, 2008
    Applicant: HELIXIR CO., LTD
    Inventors: Mi Rim JIN, Jae Ha RYU, Hyoun Jeong CHOI, Hyun Jin JUNG, Kyoung Chul PARK, Sun Young KIM
  • Patent number: 6150390
    Abstract: The present invention relates to a novel 3-amino-1,2-benzoisoxazole derivatives, represented by Formula I, LTB-4[leukotriene-B-4; 5(S),12(R)-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid] receptor antagonist, process for preparation thereof, and use thereof for LTB-4 receptor antagonist or therapeutics for osteoporosis. ##STR1## (in which n is integer of 3-5).
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: November 21, 2000
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Hong-Suk Suh, Jae-Ha Ryu, Yong-Nam Han, Sung-June Yoon, Jong-Woo Kim